Multi-Center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS.
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ENER-G
- Sponsors Biogen Idec
- 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Apr 2011 Results presetned at the 63rd Annual Meeting of the American Academy of Neurology, according to a Biogen Idec media release.
- 29 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.